ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 5 of 45
Up
УЖМБС 2021, 6(6): 44–56
https://doi.org/10.26693/jmbs06.06.044
Experimental Medicine and Morphology

Features of the Lymphoid Microenvironment in Invasive Ductal Breast Cancer

Volos L. I., Dudash A. P.
Abstract

The purpose of the study was to assess the distribution of tumor-infiltrating T-, B-lymphocytes and natural killer cells in various molecular subtypes of invasive ductal breast cancer and to establish their relationship with the degree of tumor differentiation. Materials and methods. The basis of the scientific work was a complex morphological, including immunohistochemical study of 193 cases of invasive ductal breast cancer. General histological processing of the samples was carried out in accordance with the standard technique. Immunohistochemical studies for CD3, CD20, CD56, ER, PR, c-erbB2, Ki-67 were performed according to the manufacturer's protocol with the control of samples. The grade of malignancy was determined according to the modified scheme of P. Scarff, H. Bloom and W. Richardson. The presence, localization, and expression intensity of diagnostic and prognostic biomarkers CD3, CD20, and CD56-positive cells (T-, B-, and natural killer cells, respectively) were determined using the new bioimage analysis software QuPath. Results and discussion. The differences obtained in our study varied depending on the subpopulations of immune cells and their location in the tumor tissue. The density of T and B lymphocytes was higher within the tumor and in the invasive margin in the non-luminal phenotypes compared to the luminal A and B phenotypes. Compared to the density of T-lymphocytes, the B-cell infiltrate was significantly (p <0.01) less pronounced in tumors of both luminal and non-luminal phenotypes. The lowest density of natural killer cells among tumor-infiltrating lymphocytes was found within the tumor of luminal subtypes. The percentage of infiltrates of T and B cells both within the tumor focus and in the invasive margin, as well as natural killer cells in the invasive margin, was significantly lower with G1 and G2 than with the degree of differentiation G3 (p <0.01). As for intratumoral natural killer cells, differences were found only between the degree of differentiation of G2 and G3, and the differences between G1 and G2 were not statistically significant (p> 0.05). Qualitative and quantitative assessment of the intensity of expression of T-, B- and natural killer cells also demonstrated a different degree of expression of lymphocytes, depending on the molecular subtype and location of the infiltrate. The luminal subtype A was characterized by a significant predominance of mild expression (2+) CD3 both within the tumor and in the invasive margin of the tumor (p <0.05), while in the luminal B and Her2 + phenotypes, the intensity of CD3 expression prevailed at the 1+ level. Triple negative tumors were characterized by strong expression of (3+) CD3 within the tumor and in the invasive margin of the tumor in all cases studied. Conclusion. Thus, tumor-infiltrating lymphocytes in different molecular subtypes of invasive ductal breast cancer can be considered a prognostic biomarker. Our results indicate a relationship between lymphoid infiltrate and the degree of differentiation in invasive ductal breast cancer, especially in less favorable molecular subtypes

Keywords: invasive ductal breast cancer, tumor-infiltrating lymphocytes

Full text: PDF (Ukr) 596K

References
  1. WHO, 2021 Breast cancer now most common form of cancer: WHO taking action. Available from: https://www.who. int/news/item/03-02-2021-breast-cancer-now-most-common-form-of-cancer-who-taking-action
  2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. PMID: 10963602. https://doi.org/10.1038/35021093
  3. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-2675. PMID: 15571950. https://doi.org/10.1016/j.ejca.2004.08.021
  4. Strehl JD, Wachter DL, Fasching PA, Beckmann MW, Hartmann A. Invasive breast cancer: recognition of molecular subtypes. Breast Care. 2011;6:258-64. PMID: 22135623. PMCID: PMC3225209. https://doi.org/10.1159/000331339
  5. Guarneri V, Conte PF. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009;14:645-656. PMID: 19608638. https://doi.org/10.1634/theoncologist.2009-0078
  6. Huang Y, Nayak S, Jankowitz R, Davidson NE, Oesterreich S. Epigenetics in breast cancer: what's new? Breast Cancer Res. 2011;13:225. PMID: 22078060. PMCID: PMC3326545. https://doi.org/10.1186/bcr2925
  7. Place AE, Huh SJ, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13:227. PMID: 22078026. PMCID: PMC3326543. https://doi.org/10.1186/bcr2912
  8. Tan J, Buache E, Chenard MP, Dali-Youcef, Rio MC. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol. 2011;55:851-859. PMID: 21948738. https://doi.org/10.1387/ijdb.113365jt
  9. Ahn S, Chung YR, Seo AN, Kim M, Woo JW, Park SY. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. PLoS ONE. 2020;15(5):e0233037. PMID: 32401825. PMCID: PMC7219779. https://doi.org/10.1371/journal.pone.0233037
  10. Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathol (Phila). 2017 Feb;49:141-155. PMID: 28049579. https://doi.org/10.1016/j.pathol.2016.10.010
  11. Fuchs TL, Pearson A, Pickett J, Diakos C, Dewar R, Chan D, et al. Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. Pathology. 2020;52(5):515-521. PMID: 32553444. https://doi.org/10.1016/j.pathol.2020.04.004
  12. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71. PMID: 25214542. PMCID: PMC6267863. https://doi.org/10.1093/annonc/mdu450
  13. Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015 Jul;68(7):506-10. PMID: 25750267. https://doi.org/10.1136/jclinpath-2015-202944
  14. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat. 2012 Apr;132(2):545-53. PMID: 21671016. https://doi.org/10.1007/s10549-011-1620-1
  15. Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang XY, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med. 2013 Jun 12;11:145. PMID: 23758773. PMCID: PMC3694475.
  16. https://doi.org/10.1186/1479-5876-11-145
  17. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016 Oct 18;4:59. PMID: 27777769. PMCID: PMC5067916. https://doi.org/10.1186/s40425-016-0165-6.
  18. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 17;109(6):1676-84. PMID: 23982600. PMCID: PMC3777002. https://doi.org/10.1038/bjc.2013.493
  19. Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. 2016;29;1155-1164. PMID: 27363491. https://doi.org/10.1038/modpathol.2016.109
  20. Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. The Breast. 2017;35:142-150. PMID: 28735162. https://doi.org/10.1016/j.breast.2017.07.005
  21. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. PMID: 25939896. PMCID: PMC4511219. https://doi.org/10.1093/annonc/mdv221
  22. WHO Classification of Tumors Editorial Board, ed. WHO classification of tumors. 5th edition. Breast tumors. Lyon: International Agency for Research on Cancer; 2019. PMID: 32056259. https://doi.org/10.1111/his.14091
  23. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-10. PMID: 1757079. https://doi.org/10.1111/j.1365-2559.1991.tb00229.x
  24. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013. PMID: 24101045. https://doi.org/10.1200/JCO.2013.50.9984.
  25. Amat S, Penault-Llorca F, Cure H, Le Bouedëc G, Achard JL, Van Praagh I, et al. Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol. 2002;4:791-796. PMID: 11894126. https://doi.org/10.3892/ijo.20.4.791
  26. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016 Oct 18; 4:59. PMID: 27777769. PMCID: PMC5067916. https://doi.org/10.1186/s40425-016-0165-6.
  27. Kim JY, Heo SH, Choi SK, Song IH, Park IA, Kim YA, et al. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes. Virchows Arch. 2017 Apr;470(4):381-389. PMID: 28185053. https://doi.org/10.1007/s00428-017-2083-5
  28. Tsang JY, Hui SW, Ni YB, Chan SK. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers. Breast Cancer Res Treat. 2014 Jan;143(1):1-9. PMID: 24272079. https://doi.org/10.1007/s10549-013-2781-x
  29. Nagalla S, Chou JW, Willingham MC, Ruiz J. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013 Apr 29;14(4):R34. PMID: 23618380. PMCID: PMC3798758. https://doi.org/10.1186/gb-2013-14-4-r34
  30. Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Med. 2016 Dec 13;13(12):e1002194. PMID: 27959923; PMCID: PMC5154505. https://doi.org/10.1371/journal.pmed.1002194
  31. Lyndin MS, Romaniuk AM. Invazyvnyi rak nespetsyfichnoho typu molochnoi zalozy: histolohichni ta imunohistokhimichni osoblyvosti [Invasive cancer of non-specific type of breast: histological and immunohistochemical features]. Challenges of medical science and education: an experience of EU countries and practical introduction in Ukraine: Collective monograph. Riga: Izdevnieciba "Baltija Publishing"; 2020. 344 р. Chapt 8; p. 264-281.
  32. https://doi.org/10.30525/978-9934-588-64-8-15
  33. Cimino-Mathews A, Ye X, Meeker A, Argani P, Emens LA. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Hum Pathol. 2013 Oct;44(10):2055-63. PMID: 23701942. PMCID: PMC3758372. https://doi.org/10.1016/j.humpath.2013.03.010
  34. Gao Zh, Li CX, Liu M, Jiang JY. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020;20:1150. PMID: 33238978. PMCID: PMC7690150. https://doi.org/10.1186/s12885-020-07654-y
  35. Angelico G, Broggi G, Caltabiano R, Santoro A. Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer. Appl Sci. 2021;11:6788. https://doi.org/10.3390/app11156788
  36. Fu Z, Zuo Y, Li D, Xu W, Li D, Chen H, et al. The crosstalk: Tumor-infiltrating lymphocytes rich in regulatory T cells suppressed cancer-associated fibroblasts. Acta Oncol. 2013 Nov;52(8):1760-70. PMID: 23336253. PMCID: PMC3812699. https://doi.org/10.3109/0284186X.2012.760847
  37. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 17;109(6):1676-84. PMID: 23982600. PMCID: PMC3777002. https://doi.org/10.1038/bjc.2013.493
  38. Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017 Aug;71(2):258-268. PMID: 28326600. https://doi.org/10.1111/his.13217
  39. Helal TE, Ibrahim EA, Alloub AI. Immunohistochemical analysis of tumor-infiltrating lymphocytes in breast carcinoma: relation to prognostic variables. Indian J Pathol Microbiol. 2013 Apr-Jun;56(2):89-93. PMID: 24056641. https://doi.org/10.4103/0377-4929.118676
  40. Engels CC, Fontein DB, Kuppen PJ, de Kruijf EM, Smit VT, Nortier JW, et al. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma. Br J Cancer. 2014 Jul 29;111(3):532-8. PMID: 24937677. PMCID: PMC4119991. https://doi.org/10.1038/bjc.2014.338
  41. Roncati L, Barbolini G, Piacentini F, Piscioli F, Pusiol T, Maiorana A. Prognostic Factors for Breast Cancer: An Immunomorphological Update. Pathol Oncol Res. 2016 Jul;22(3):449-52. PMID: 26589512. https://doi.org/10.1007/s12253-015-0024-7